Litcius/Paper detail

Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants

Beilei Wang, Wentao Zhang, Xuesong Liu, Fengming Zou, Jun‐Jie Wang, Qingwang Liu, Qingwang Liu, Aoli Wang, Zhenquan Hu, Yongfei Chen, Shuang Qi, Zongru Jiang, Cheng Chen, Chen Hu, Li Wang, Wenchao Wang, Qingsong Liu, Qingsong Liu, Jing Liu

2020European Journal of Medicinal Chemistry18 citationsDOIOpen Access PDF

Topics & Concepts

Trk receptorTropomyosin receptor kinase AKinomeChemistryIn vivoKinaseMutantPharmacologyBiochemistryNeurotrophinBiologyReceptorGeneBiotechnologyMelanoma and MAPK PathwaysQuinazolinone synthesis and applicationsCancer Mechanisms and Therapy
Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants | Litcius